Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|December 28, 2015
Dr. Maurie Markman on Developing Research Into Checkpoint Inhibitors in Ovarian Cancer
Author(s)Maurie Markman, MD
Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.
Advertisement
Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors. Markman says only recently have papers been published on checkpoint inhibitors in the treatment of ovarian cancers, marking just how far behind research is on the topic compared to other cancers.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5